BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1649 related articles for article (PubMed ID: 25909322)

  • 1. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
    Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
    PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells in hepatocellular carcinoma patients.
    Liu YK; Hu BS; Li ZL; He X; Li Y; Lu LG
    Hepatol Int; 2016 Jul; 10(4):640-6. PubMed ID: 27115761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer.
    Zhao R; Cai Z; Li S; Cheng Y; Gao H; Liu F; Wu S; Liu S; Dong Y; Zheng L; Zhang W; Wu X; Yao X
    Oncotarget; 2017 Feb; 8(6):9293-9302. PubMed ID: 28030836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response.
    Li TT; Liu H; Li FP; Hu YF; Mou TY; Lin T; Yu J; Zheng L; Li GX
    World J Gastroenterol; 2015 Dec; 21(47):13259-67. PubMed ID: 26715808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.
    Krebs MG; Hou JM; Sloane R; Lancashire L; Priest L; Nonaka D; Ward TH; Backen A; Clack G; Hughes A; Ranson M; Blackhall FH; Dive C
    J Thorac Oncol; 2012 Feb; 7(2):306-15. PubMed ID: 22173704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
    Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
    World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
    Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
    Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer.
    Li S; Chen Q; Li H; Wu Y; Feng J; Yan Y
    Clin Transl Oncol; 2017 Sep; 19(9):1147-1153. PubMed ID: 28374320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial-mesenchymal transition phenotypes of circulating tumor cells correlate with the clinical stages and cancer metastasis in hepatocellular carcinoma patients.
    Chen J; Cao SW; Cai Z; Zheng L; Wang Q
    Cancer Biomark; 2017 Dec; 20(4):487-498. PubMed ID: 28869439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial-mesenchymal transition and GALC expression of circulating tumor cells indicate metastasis and poor prognosis in non-small cell lung cancer.
    Liu DG; Xue L; Li J; Yang Q; Peng JZ
    Cancer Biomark; 2018; 22(3):417-426. PubMed ID: 29758927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
    Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
    Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application.
    Chen F; Wang S; Fang Y; Zheng L; Zhi X; Cheng B; Chen Y; Zhang C; Shi D; Song H; Cai C; Zhou P; Xiong B
    Oncotarget; 2017 Jan; 8(2):3029-3041. PubMed ID: 27935872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Tumor Cells and Implications of the Epithelial-to-Mesenchymal Transition.
    Lowes LE; Allan AL
    Adv Clin Chem; 2018; 83():121-181. PubMed ID: 29304900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enrichment and enumeration of circulating tumor cells by efficient depletion of leukocyte fractions.
    Wu S; Liu Z; Liu S; Lin L; Yang W; Xu J
    Clin Chem Lab Med; 2014 Feb; 52(2):243-51. PubMed ID: 24021598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients.
    Bock C; Rack B; Huober J; Andergassen U; Jeschke U; Doisneau-Sixou S
    Future Oncol; 2014 Aug; 10(10):1751-65. PubMed ID: 25303055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients.
    Togo S; Katagiri N; Namba Y; Tulafu M; Nagahama K; Kadoya K; Takamochi K; Oh S; Suzuki K; Sakurai F; Mizuguchi H; Urata Y; Takahashi K
    Oncotarget; 2017 May; 8(21):34884-34895. PubMed ID: 28432274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer.
    Chen J; Cao S; Situ B; Zhong J; Hu Y; Li S; Huang J; Xu J; Wu S; Lin J; Zhao Q; Cai Z; Zheng L; Wang Q
    J Exp Clin Cancer Res; 2018 Jun; 37(1):127. PubMed ID: 29954422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 83.